Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid

1/2期 已完成 NCT00584935

摘要

Cicatricial pemphigoid is an autoimmune blistering disease which affects the skin, mucous membranes, and, in a small subset of patients, the eye. Progressive ocular disease can lead to irreversible damage and blindness. Conventional treatments include systemic steroids, dapsone, and immunosuppressive agents. These treatments, however, are not successful with all patients. Rituximab has been very effective in the treatment of other autoimmune disorders, and has recently been shown to be effective for autoimmune blistering pemphigus. We propose that it will also be effective in the treatment of cicatricial pemphigoid.

Number of Participants With no Evidence of Further Scarring (Fosters Staging) at 16 Weeks

16 weeks · participants

2. The Proportion of Patients That Experience a Grade 3, Grade 4, or Grade 5 Toxicity Based Reaction on the NCI-CTC System at the Time of Their Infusions and During Follow-up Visits.

16 weeks

在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文

全部试验